| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.6 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |